BioNxt Solutions Inc. (CSE:BNXT)

Market Cap	55.12M -30.0%
Revenue (ttm)	n/a
Net Income	-9.14M
EPS	-0.07
Shares Out	136.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	44,444
Open	0.4050
Previous Close	0.3900
Day's Range	0.4050 - 0.4050
52-Week Range	0.2800 - 0.9100
Beta	1.50
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 27, 2026

About BioNxt Solutions

BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis and myasthenia gravis; BNT24002 for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; BNT24005 for solid organic transplantation; and BNT24006, an oncology drug targeting chemotherapy platform and anticancer mTOR inhibitor. It also ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2017
• Employees: 20
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: BNXT

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 18, 2026

Data Sources Report a data error